Stockscreener 앱 받기
8.43
0.48%
0.04
시간 외 거래:
8.43
Kura Oncology Inc 주식(KURA)의 최신 뉴스
Kura Oncology Inc Stock (ISIN: US50126D1028) Faces Post-Earnings Pressure Amid Komzifti Launch Chall - AD HOC NEWS
Kura Oncology, Inc. (NASDAQ:KURA) Q4 2025 earnings call transcript - MSN
Kura Oncology anticipates $7B AML opportunity as KOMZIFTI launches and combination strategies advance - MSN
UBS Maintains Buy on KURA (Kura Oncology) March 2026, PT $15 - Meyka
Prosight Management LP Sells 422,668 Shares of Kura Oncology, Inc. $KURA - MarketBeat
UBS lowers Kura Oncology stock price target to $15 on launch data - Investing.com Canada
KURA SEC FilingsKura Oncology Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Implied volatility surging for Kura Oncology stock options - MSN
Implied Volatility Soars for Kura Oncology Option Contracts - Bitget
Kura Oncology at Barclays Conference: Strategic Focus on Drug Combinations - Investing.com Canada
Implied Volatility Surging for Kura Oncology Stock Options - Yahoo Finance
(KURA) Risk Channels and Responsive Allocation - Stock Traders Daily
Kura Oncology Inc earnings missed by $0.66, revenue fell short of estimates - Investing.com Nigeria
Kura Oncology at Leerink Global Healthcare Conference: Strategic Expansion Insights - Investing.com Canada
KURA: Rapid market access and robust pipeline drive growth and leadership ambitions in precision oncology - TradingView
KURA: Multiple clinical readouts and strong commercial momentum position for leadership in targeted oncology - TradingView
FY2027 EPS Forecast for Kura Oncology Lowered by Analyst - MarketBeat
How The Kura Oncology (KURA) Story Is Shifting With Komzifti And New Street Targets - Yahoo Finance
UBS Reaffirms Their Buy Rating on Kura Oncology (KURA) - The Globe and Mail
Kura Oncology rises after new early-stage trial data for leukemia therapy - MSN
Jim Cramer discusses Kura Oncology as a speculative bet - MSN
Kura Oncology 2025 Financials: Q4 Loss Widens, Misses Analyst EstimatesNews and Statistics - IndexBox
Kura Oncology Q4 2025 earnings preview - MSN
Kura Oncology, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:KURA) 2026-03-06 - Seeking Alpha
Kura Oncology, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Kura Oncology Reports $0.92 Q4 Loss Even as KOMZIFTI Debuts With $2.1M in Sales - AlphaStreet
Kura Oncology (NASDAQ:KURA) Given New $36.00 Price Target at Wedbush - MarketBeat
Kura Oncology, Inc. (NASDAQ:KURA) Q4 2025 Earnings Call Transcript - Insider Monkey
Kura Oncology reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Kura Oncology (KURA) Grants Stock Options to New Employees - GuruFocus
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Kura Oncology Q4 Earnings Call Highlights - MarketBeat
Kura Oncology Inc (KURA) Q4 2025 Earnings Call Highlights: KOMZIFTI Launch Boosts Revenue Amid ... By GuruFocus - Investing.com Canada
Wedbush Cuts Kura Oncology Price Target to $36 From $38, Outperform Rating Maintained - marketscreener.com
Kura Oncology Inc (KURA) Q4 2025 Earnings Call Highlights: KOMZI - GuruFocus
Kura Oncology (KURA) Reports Strong Q4 2025 with KOMZIFTI Launch - GuruFocus
Kura Oncology, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Kura Oncology (NASDAQ:KURA) Shares Gap Down After Earnings Miss - MarketBeat
Kura Oncology (NASDAQ:KURA) Releases Quarterly Earnings Results, Misses Estimates By $0.20 EPS - MarketBeat
Earnings call transcript: Kura Oncology Q4 2025 sees significant earnings miss, stock dips - Investing.com
Kura Oncology (KURA) Reports Q4 Loss, Misses Revenue Estimates - sharewise.com
KURA: KOMZIFTI launch and pipeline progress drive growth, targeting major cancer markets - TradingView
Kura Oncology, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Kura Oncology Reports Q4 Earnings Miss - National Today
Kura Oncology 10-K: $67.5M revenue; R&D $251.1M, SG&A $120.0M - TradingView
Kura Oncology: Q4 Earnings Snapshot - KVUE
Kura Oncology: Fourth Quarter Financial Results Overview - Bitget
Kura Oncology (KURA) Faces Mixed Financial Results Amid Promisin - GuruFocus
Earnings Flash (KURA) Kura Oncology Posts Q4 Loss $0.92 a Share, vs. FactSet Est of $0.64 Loss - marketscreener.com
KURA ONCOLOGY ($KURA) Releases Q4 2025 Earnings - Quiver Quantitative
Kura Oncology Inc. Q4 Loss Increases - Nasdaq
Kura Oncology Reports Early Commercial Success for KOMZIFTI™ (ziftomenib) with Strong Initial Revenue and Payer Support - Quiver Quantitative
Kura Oncology Q4 Earnings Summary & Key Takeaways - Benzinga
Kura Oncology (KURA) begins KOMZIFTI sales and posts wider 2025 loss - Stock Titan
Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Kura Oncology at TD Cowen Conference: Strategic Growth and Innovation By Investing.com - Investing.com Canada
1.20%
0.06%
자본화:
|
볼륨(24시간):